Olanzapine/fluoxetine combination for bipolar depression

References

• Judd LL, Schettler PJ, Akiskal HS et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int. J. Neuropsychopharmacol. 6, 127–137 (2003).
   PubMed Web of Science ®Google Scholar
• Shelton RC. Treating bipolar depression. J Fam. Pract. (Suppl.) S14–S17 (2003).
   PubMedGoogle Scholar
• Keck PE Jr, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar depression. Biol. Psych. 53, 671–679, 4–15 (2003).
   PubMed Web of Science ®Google Scholar
• Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 57, 411–441 (1995).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Morgan WN, Plott SJ et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305–1322 (1997).
   PubMed Web of Science ®Google Scholar
• Lemberger L, Bergstrom RF, Wolen RL et al. Fluoxetine: clinical pharmacology and physiologic disposition. J. Clin. Psych. 46, 14–19 (1985).
   Web of Science ®Google Scholar
• Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17, 263–287 (1991).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, HemrickLuecke SK, Perry KW et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124, 87–94 (1996).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87–96 (1996).
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Baldessarini RJ, Kula NS et al. Long-term effects of Olanzapine, Risperidone, and Quetiapine on Ionotropic glutamate receptor types: Implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 306, 1145–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bastani B, Ramirez L et al. Clozapine: new research on efficacy and mechanism of action. Eur. Arch. Psychiatry Neurol. Sci. 238, 332–339 (1989).
   Google Scholar
• Meltzer HY, Li Z, Kaneda Y et al. Serotonin receptors : their key role in drugs to treat schizophrenia. Biol. Psych. 1159–1172 (2003).
   Google Scholar
• Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr. Res. 35(Suppl.) S13–S21 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang W, Perry KW, Wong DT et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23, 250–262 (2000).
   PubMed Web of Science ®Google Scholar
• Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin. Pharmacother. 4, 1175–1183 (2003).
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin re-uptake inhibitors in major depression. J. Clin. Psych. 60, 256–259 (1999).
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psych.158, 131–134 (2001).
   PubMed Web of Science ®Google Scholar
• Shelton RC, Williamson D, Corya SA et al. Olanzapine/fluoxetine combination for treatmentresistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psych.(2005) (In Press).
   Google Scholar
• Dube S, Teal PSS. Olanzapine-fluoxetine combination in treatment-resistant depression. Eur. Psych.17(Suppl. 1), 98–98 (2002).
   Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psych.60, 1079–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Corya SA, Altshuler LL et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J. Clin. Psych. 66, 611–616 (2005).
   Google Scholar
• Tohen M, Vieta E, Ketter TA et al. Acute and long-term efficacy of olanzapine and olanzapine/fluoxetine combination for bipolar depression. Arch. Gen. Psychiatry 60, 1079-1088, (2003).
   Google Scholar
• Williams AB, Adetunji BA. Olanzapine and olanzapine-fluoxetine combination treatment and bipolar I depression. Arch. Gen. Psych. 62, 1052 (2005).
   PubMedGoogle Scholar
• Tohen M, Baker RW, Altshuler LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psych.159, 1011–1017 (2002).
   PubMed Web of Science ®Google Scholar
• Tohen M. Olanzapine’s efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12 month clinical trial. [abstract]. Bipolar Disord. 5(Suppl. 1), 89 (2003).
   Google Scholar
• Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch. Gen. Psych. 57, 841–849 (2000).
   PubMed Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group. Am. J. Psych.156, 702–709 (1999).
   PubMed Web of Science ®Google Scholar
• McCormack PL, Wiseman LR. Spotlight on olanzapine in bipolar I disorder. CNS Drugs19, 553–555 (2005).
   PubMedGoogle Scholar
• Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 114, 559–565 (1994).
   Google Scholar
• Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21, S106–S115 (1999).
   PubMed Web of Science ®Google Scholar
• Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert. Opin. Pharmacother. 4, 1175–1183 (2003).
   PubMed Web of Science ®Google Scholar
• Meltzer HY. The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences? Int. J. Neuropsychopharmacol. 8, 153–156 (2005).
   PubMedGoogle Scholar
• Baptista T, Kin NM, Beaulieu S et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35, 205–219 (2002).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–23 (2005).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs19(Suppl. 1), 1–93 (2005).
   PubMed Web of Science ®Google Scholar
• Saito E, Correll CU, Gallelli K et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J. Child Adolesc. Psychopharmacol.14, 350–358 (2004).
   PubMed Web of Science ®Google Scholar
• Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J. Clin. Psych. 66, 761–767 (2005).
   Google Scholar
• Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf.22, 73–81 (2000).
   PubMed Web of Science ®Google Scholar
• Lauterbach EC, Carter WG, Rathke KM et al. Tardive dyskinesia-diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital in-patients referred to a movement disorder consultation service. Schizophr. Bull 27, 601–613 (2001).
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr., McElroy SL, Strakowski SM et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J. Clin. Psych. 61(Suppl. 4), 33–38 (2000).
   Google Scholar
• Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord. 5(Suppl. 2), 7–19 (2003).
   PubMedGoogle Scholar
• Dunner DL, Amsterdam JD, Shelton RC. et al. Adjunctive ziprasidone in treatment-resistant depression: randomized, double-blind, 8-week pilot study. Annual Meeting of the American College of Neuropsychopharmacology, December 12–16, San Juan, PR (2004).
   Google Scholar
• Calabrese JR, Keck PE, Jr., Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psych.162, 1351–1360 (2005).
   PubMed Web of Science ®Google Scholar
• Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J. Clin. Psych. 65, 1715–1719 (2004).
   Google Scholar
• Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psych.60, 392–400 (2003).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psych. 64, 1013–1024 (2003).
   Google Scholar
• Bowden CL, Mitchell P, Suppes T. Lamotrigine in the treatment of bipolar depression. Eur. Neuropsychopharmacol9(Suppl. 4), S113–S117 (1999).
   PubMedGoogle Scholar
• Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psych. 60, 79–88 (1999).
   Google Scholar
• Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psych.23, 56–62 (1960).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psych. 134, 382–389 (1979).
   PubMed Web of Science ®Google Scholar
• Seemuller F, Forsthoff A, Dittmann S et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin. Drug Saf.4, 849–868 (2005).
   Google Scholar
• Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psych. Serv. 52, 967–969 (2001).
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust. N. Z. J. Psych.39, 479–486 (2005).
   PubMed Web of Science ®Google Scholar
• Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J. Clin. Psych. 1045 (2003).
   Google Scholar
• Henderson DC, Copeland PM, Daley TB et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am. J. Psych.162, 954–962 (2005).
   PubMed Web of Science ®Google Scholar
• Cavazzoni P, Tanaka Y, Roychowdhury SM et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur. Neuropsychopharmacol.13, 81–85 (2003).
   PubMed Web of Science ®Google Scholar
• Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am. J. Psych.159, 655–657 (2002).
   PubMed Web of Science ®Google Scholar
• Deberdt W, Winokur A, Cavazzoni PA et al. Amantadine for weight gain associated with olanzapine treatment. Eur. Neuropsychopharmacol.15, 13–21 (2005).
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Isaacs I, Fuchs C et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am. J. Psych.160, 297–302 (2003).
   PubMed Web of Science ®Google Scholar
• Straker D, Correll CU, Kramer-Ginsberg E et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am. J. Psych.162, 1217–1221 (2005).
   PubMed Web of Science ®Google Scholar
• Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord. 5(Suppl. 2), 62–79 (2003).
   Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care28, S4–S36 (2005).
   PubMed Web of Science ®Google Scholar